13
CHAPTER 1 ABSTRACT Guillain-Barré syndrome is a heterogeneous condition with several variant forms that is the most common cause of acute flaccid paralysis in both children and adults. It is estimated that the condition affects about 1 to 3 individuals per 100,000 persons. Patients typically complain of increasing pain and weakness in the limbs associated with tingling dysesthesias in the extremities. The majority of patients with Guillain-Barré have been diagnosed with an infection in the 3 weeks prior to the development of symptoms. Other events that have been linked to the disorder include vaccinations, surgery, and certain drugs. Therapy includes immunotherapy to accelerate the recovery process as well as specific therapies for individual patients such as pain relief. INTRODUCTION Guillain-Barré syndrome (GBS) is a heterogeneous condition associated with immunemediated, reactive, self-limiting peripheral neuropathies. It represents at least five different entities that are associated with an increased concentration of cerebrospinal fluid protein but a normal cell count and manifest as systemic motor paralysis. Three of these forms predominantly affect the motor system: acute motor axonal neuropathy (AMAN), acute motor-sensory axonal neuropathy

refrat GBS

Embed Size (px)

DESCRIPTION

qwerty

Citation preview

CHAPTER 1

ABSTRACTGuillain-Barr syndrome is a heterogeneous condition with several variant forms that is the most common cause of acute flaccid paralysis in both children and adults. It is estimated that the condition affects about 1 to 3 individuals per 100,000 persons. Patients typically complain of increasing pain and weakness in the limbs associated with tingling dysesthesias in the extremities. The majority of patients with Guillain-Barr have been diagnosed with an infection in the 3 weeks prior to the development of symptoms. Other events that have been linked to the disorder include vaccinations, surgery, and certain drugs. Therapy includes immunotherapy to accelerate the recovery process as well as specific therapies for individual patients such as pain relief.

INTRODUCTIONGuillain-Barr syndrome (GBS) is a heterogeneous condition associated with immunemediated, reactive, self-limiting peripheral neuropathies.It represents at least five different entities that are associated with an increased concentration of cerebrospinal fluid protein but a normal cell count and manifest as systemic motor paralysis.Three of these forms predominantly affect the motor system: acute motor axonal neuropathy (AMAN), acute motor-sensory axonal neuropathy (AMSAN), and acute inflammatory demyelinating polyradiculoneuropathy (AIDP).The other two variants are Miller Fisher syndrome and acute pandysautonomic neuropathy.The disorder, triggered by a preceding bacterial or viral infection, causes respiratory failure requiring mechanical ventilation in approximately 25% of cases.Mortality rates in patients requiring mechanical ventilation are as high as 20%, with persistent disability and persistent fatigue in 20% and 67% of patients, respectively.

CHAPTER 2

DEFINITIONGuillain-Barr syndrome (GBS) is disorder in which the bodys immune system attacks part of the peripheral nervous system, described best as a polyradiculoneuropathy. With the widespread eradication of poliomyelitis, GBS is the most common cause of acute and subacute flaccid paralysis in infants and children. The disorder is characterized by progressive, symmetrical, usually ascending weakness, and diminished or absent reflexes starting from legs. Diffuse pain also is a common presenting feature in many children with GBS, at times delaying accurate diagnosis. GBS was thought previously to be an inflammatory disorder that affected only the myelin sheath, resulting in diffuse demyelination. However, it is now recognized that the process can also attack the axon, leading to degeneration of the nerve itself.After the first clinical manifestations of the disease, the symptoms can progress over the course of hours, days, or weeks. Most people reach the stage of greatest weakness within the first 2 weeks after symptoms appear, and by the third week of the illness 90 percent of all patients are at their weakest.

EPIDEMIOLOGYGBS occurs year round and in all age groups. Adults are affected more commonly than children. Some studies suggest that males are more likely to be affected than females. The overall incidence has been estimated to range from 0.4 to 2.4 cases per 100,000 per year, with 3,500 new cases per year occurring in the United States. The incidence in children is lower, with estimates between 0.4 and 1.3 cases per 100,000 per year. GBS can occur at any age but is rare in children under the age of 2 years.

ETIOLOGYGuillain- Barr syndrome is an autoimmune disease in which the immune system destroys the cover of peripheral nerves ( myelin fibers ) by blocking the transmission of nerve to muscle . If this happens , the muscles do not have a response to a command from the central nervous and can lead to weakness , numbness and paralysis . The brain also receives sensory signals that lead to a state of not feeling well , chills , pain and other sensations .Some state / disease which precedes and may related with the GBS : infection vaccination surgery Systemic diseases :o malignancyo systemic lupus erythematosuso thyroiditiso Addison's disease Pregnancy or the puerperiumGBS often associated with acute non-specific infections. Incidence GBS cases associated with this infection approximately between 56 % - 80 % , 1 up to 4 weeks before neurological symptoms arise such as respiratory tract infections above or gastrointestinal infection.

InfectionDefiniteProbablePossible

ViralCMVEBVHIV Varicella-zoster Vaccinia/smallpoxInfluenza Measles Mumps Rubella Hepatitis Coxsackie Echo

BacteriaCampylobacter Jejeni Mycoplasma PneumoniaTyphoidBorrelia B ParatyphoidBrucellosis Chlamydia Legionella Listeria

PATHOPHYSIOLOGYBecause this disease involving motor axonal degeneration without inflammation , other terms of this syndrome is acute axonal neuropathy motors ( AMAN) . Paralysis of the limbs showed signs of LMN , bulbar paralysis sometimes accompanies such tetraparalisis , even can also occur only cranial sensory and motor paralysis are found .In the demyelinating form , segmental demyelination of peripheral nerves met with inflammatory cells. Guillain- Barr syndrome with axonal degeneration can occur without demyelination or inflammation .Mechanisms of disease occurs due to excessive response of T cells from the abnormal previous infection . CD4 + helper - inducer T cells are important mediators of the disease . Various specific antigens may be involved in this response , including Myelin P - 2 and ganglioside GM1.

CLINICAL MANIFESTATIONGBS manifests as a rapidly evolving areflexic motor paralysis with or without disturbance. The usual pattern is an ascending paralysis that may be first notice as rubbery legs. Weakness typically evolves over hours to a few days and is frequently accompanied by tingling dysesthesias in the extremities. The legs are usually more affected than the arms, and facial diparesis is present in 50 % of affected individuals. The lower cranial nerves are also frequently involved, causing bulbar weakness with difficulty handling secretions and maintaining an airway. Pain in the neck, shoulder, back, or diffusely over the spine is also common in early stages of GBS, occurring in 50 % of patients. Deep tendon reflexes attenuate or disappear within the first few days of onset. Cutaneous sensory deficits (e.g., loss of pain and temperature sensation) are usually relatively mild, but functions subserved by large sensory fibers, such as deep tendon reflexes and proprioception, are more severely affected. Bladder dysfunction may occur in severe cases but is usually transient. Autonomic involvement is common and may occur even in patients whose GBS is otherwise mild. The usual manifestations are loss of vasomotor control with wide fluctuation in blood pressure, postural hypotension, and cardiac dysrhythmias.SubtypeFeaturesElectrodiagnosisPathology

Acute inflammatory demyelinating polyneuropathy (AIDP)Adults affected more than children; 90% of cases ; recovery rapid; anti-GM1 antibodies (